

Registered number: 2877400  
Charity number: 1030623

---

**BRITISH PHARMACOLOGICAL SOCIETY**

---

**TRUSTEES REPORT AND FINANCIAL STATEMENTS**

**FOR THE YEAR ENDED 31 DECEMBER 2014**

---

**BRITISH PHARMACOLOGICAL SOCIETY**

---

**CONTENTS**

---

	Page
<b>Reference and administrative details of the charity, its trustees and advisers</b>	1 - 2
<b>Trustees' report</b>	3 - 16
<b>Independent auditors' report</b>	17 - 18
<b>Statement of financial activities</b>	19
<b>Balance sheet</b>	20
<b>Notes to the financial statements</b>	21 - 39

---

## BRITISH PHARMACOLOGICAL SOCIETY

---

### REFERENCE AND ADMINISTRATIVE DETAILS OF THE CHARITY, ITS TRUSTEES AND ADVISERS

---

#### **Trustees**

H P Rang  
D J Webb  
C R Hiley  
A Galione  
A H Morice  
A R Green  
D M Wood  
M P Seed  
S Price  
C Williams (until 31 December 2014)  
A K Daly (until 31 December 2014)  
D O Douglas (until 31 December 2014)  
E Mason (from 1 January 2015)

#### **Company registered number**

2877400

#### **Charity registered number**

1030623

#### **Registered office**

The Schild Plot  
16 Angel Gate  
City Road  
London  
EC1V 2PT

#### **Chief Executive**

J Brūn

#### **Company Secretary**

M Poole

#### **Independent auditors**

French Duncan LLP  
Chartered Accountants & Statutory Auditor  
56 Palmerston Place  
Edinburgh  
EH12 5AY

---

## BRITISH PHARMACOLOGICAL SOCIETY

---

### REFERENCE AND ADMINISTRATIVE DETAILS OF THE CHARITY, ITS TRUSTEES AND ADVISERS

---

#### **Advisers (continued)**

##### **Bankers**

Cooperative Bank plc  
1 Islington High Street  
London  
N1 9TR

Barclays Bank plc  
1st Floor  
27 Soho Square  
London  
W1D 3QR

##### **Solicitors**

Taylor Vinters LLP  
Merlin Place  
Merlin Road  
Cambridge  
CB4 0DP

##### **Investment managers**

Brewin Dolphin  
12 Smithfield Street  
London  
EC1A 9BD

##### **VAT Consultants**

Haslers  
Chartered Accountants  
Old Station Road  
Loughton  
IG10 4PL

---

## BRITISH PHARMACOLOGICAL SOCIETY

---

### TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2014

---

#### OBJECTIVES AND ACTIVITIES

##### **Our Mission Statement**

The aim of the Society is to promote and advance pharmacology, including clinical pharmacology. The direct beneficiaries are the members of the pharmacology community worldwide; indirectly, society in general benefits from the enhanced education and training of scientists and clinicians and the dissemination of research, which lead to improvements in health.

##### **Strategies for Achieving Objectives**

BPS Council ratified in March 2012 a five-year strategy. Five key priorities were agreed and are listed below, forming the basis of the Society's strategy to 2017. A review was completed in 2014, to be ratified by Council in early 2015 and to inform the development of a post-2017 strategy.

This strategy has determined the basis for the work of the Society's over this period.

##### *Key principles*

There are two overarching principles to be taken into account, when considering all future BPS activities, namely:

- achieving financial resilience and
- further development and modernisation of the Society's equality and diversity policy

##### *Our Key Priorities*

- Greater matching of the Society's activities to the needs of the Membership.
- Development of an integrated publications strategy.
- Explaining the importance of pharmacology in the modern world by extending BPS teaching and outreach activities.
- To reflect the increasingly multi-disciplinary nature of modern biomedical science by further developing BPS's collaborative activities with other Societies.
- BPS should maintain its central position in the promotion of clinical pharmacology, the promotion of safe and effective prescribing, and in the discovery and development of medicines in the UK.

The Society's activities were focused on achieving these objectives throughout the year, as set out in pages 5 to 9.

---

## BRITISH PHARMACOLOGICAL SOCIETY

---

### TRUSTEES' REPORT (continued) FOR THE YEAR ENDED 31 DECEMBER 2014

---

#### OBJECTIVES AND ACTIVITIES (continued)

##### Grant Making Policies

The Society's policy is to make grants that advance its objectives, i.e. to promote and advance pharmacology, and to comply with the terms of any restricted or designated funds from which grants are provided. Applications are invited from individuals or institutions suitably qualified or active in the discipline. Appropriate committees decide who will receive grants. In the case of a few minor grants, authority to make decisions on applications is delegated to individual officers or senior staff.

##### Public Benefit Statement

Pharmacology is responsible for the discovery of hundreds of chemicals used in the treatment of disease and the relief of human and animal suffering, as well as contributing substantially to the success of the pharmaceutical and healthcare industries.

The British Pharmacological Society's mission is to promote and advance pharmacology, including clinical pharmacology. As a primary UK learned society concerned with research into drugs and the way they work, the Society's strategic objectives deliver both this mission and the following public benefits:

- Fostering excellence in scientific discovery by providing new opportunities for pharmacologists to present and publish their research, and supporting their development of new skills.
- Improving clinical practice for the benefit of patients through the assessment and training of healthcare professionals and medical students
- Educating the general public and schools students with engaging outreach activities

The Trustees confirm that they have complied with the duty in Section 4 of the Charities Act 2006 to have due regards to the Charity Commission's general guidance on public benefit "Charities and Public Benefit"

---

## BRITISH PHARMACOLOGICAL SOCIETY

---

### TRUSTEES' REPORT (continued) FOR THE YEAR ENDED 31 DECEMBER 2014

---

#### ACHIEVEMENTS AND PERFORMANCE

##### 1. STRATEGIC PRINCIPLE: Achieving financial resilience

###### **Conduct and implement a Digital Strategy, with a focus on supporting greater e-commerce potential from BPS online activities**

- A thoughtful and future-focused Digital Strategy was developed, with input from members and staff, which has identified new opportunities and created action plans for enhancing member services, e-commerce and public engagement.
- The Society launched a new member database in June 2014, which integrated member services, communications and financial systems for the first time. This has already provided the Society with a clearer picture of the needs of the pharmacology community.
- The Society commissioned a new BPS website, as well as research into the Society's branding and reputation among members and external audiences. Both projects will be completed in mid-2015, in order to modernize and protect the image of the Society in the 21st century.

###### **Build capacity within the Society and among its staff to deliver a range of new revenue-based initiatives**

- The Society benefited from the development of improved management accounts and information in 2014, as well as an intensive, government-backed Growth Accelerator training programme for staff, including training sessions on financial skills, innovation and management. These have helped the Society to respond to new revenue generating opportunities, including in the delivery of scientific meetings and educational projects.
- Following a needs assessment of business development support, the Society advertised for a new fixed term Head of Innovation and Product Development who will be recruited in the first half 2015. This new team member will have responsibility for recommending new commercial opportunities for the Society, in new and existing programmes of work which will balance our continued delivery of core charitable activities.

##### 2. STRATEGIC PRINCIPLE: Modernizing equality and diversity policy

###### **Demonstrate significant progress towards the agreed goal of 25% representation of women at BPS committees and activities**

- Across all Committees and scientific meetings, the Society has reached an average level of representation of women of 30%. Most notably the Education & Training Committee has increased participation by women from 23.5% to 40%.

###### **Put into action steps agreed by Executive Committee and Council to support and promote Equality and Diversity throughout BPS membership**

- The Women in Pharmacology Committee published interviews with established female scientists as part of a visibility series called 'Inspiring Women: Role models'.
- The Society offered 'Women in Leadership' training free to our members and is committed to offering the training again in 2015.
- The new membership database began collecting information about members in line with the recommendations of the UK's Higher Education Statistics Agency and Equality Challenge Unit. This information will be used in future planning to help the Society address unmet needs and emulate the progress made with women in pharmacology for other groups of members.

---

## BRITISH PHARMACOLOGICAL SOCIETY

---

### TRUSTEES' REPORT (continued) FOR THE YEAR ENDED 31 DECEMBER 2014

---

#### Lead and develop best practice in equality and diversity throughout the life science sector

- The Society's evidence submitted to the House of Commons' Science & Technology Committee inquiry on women in STEM careers was selected for inclusion in the Committee's report in February 2014.

#### 3. STRATEGIC OBJECTIVE: Greater matching of the Society's activities to the needs of the Membership

##### Membership numbers as at 31 December 2014:

	31 Dec 2014	31 Dec 2013
Honorary Fellows	98	88
Fellows	198	198
Retired Members	453	427
Members	1,169	1,240
Associates and Affiliates	249	234
Associate Postgraduate Students	395	392
Associate Undergraduate Students	1,091	881
Total	<u>3,653</u>	<u>3,460</u>

- 679 new members joined in 2014 and the Society has been particularly successful at attracting Undergraduate Associates; the Society is developing a strategy to increase retention of existing members and converting Associates to full membership.

#### Deliver the activities and priorities mandated by BPS members in the 2013 Member Engagement Survey

- The Society welcomed a very many members (bringing the total membership to 3,653 by December 2014) with the help of a redesigned welcome pack and materials.
- The Society delivered a survey of lapsing members, an audit of membership data and a retention strategy to ensure membership continues to grow.
- Over 300 attendees participated in member events in the UK and overseas during 2014, to help members keep up-to-date on developments in pharmacology and form collaborations with other scientists
- Scoping work was completed to identify opportunities for growing local networks of members, and a proposal for a pilot project based on this work will be reviewed by Council in 2015
- Member communications were enhanced with an upgrade of the Society's e-newsletter software in June 2014

#### In line with the outcomes of the 2013 Governance Review, and in order to reflect the changing needs of our membership, modernise the Society's constitution and present to BPS members for consideration at the 2014 AGM

- Based on the work of Council's Governance Review Working Group in 2014, updates to the Society's governing structures and documents were developed. These aimed to simplify decision-making, devolving all but key strategic and financial decisions to the core committees, and preserve BPS as a friendly, responsive and highly professional membership organization that is able to maintain its enviable reputation in the outside world

---

## BRITISH PHARMACOLOGICAL SOCIETY

---

### TRUSTEES' REPORT (continued) FOR THE YEAR ENDED 31 DECEMBER 2014

---

- Following a consultation with members a special resolution was passed at the 2014 AGM on 17 December with an overwhelming majority of members voting in favour of the new BPS constitution which took effect from 1 January 2015.

#### **Apply market research principles and greater member engagement to the decision-making process around BPS scientific meetings**

- To encourage and support member involvement in decision-making, the Society announced the creation of seven Affinity Groups in September 2014. These new groups encompassed areas previously defined by the Special Interest Groups, and it is intended that they will bring together basic and clinical expertise.
- The Meetings Committee now regularly receives information and support from the Society's marketing staff when considering new scientific meetings and events.

#### **4. STRATEGIC OBJECTIVE: Developing an integrated publications strategy**

##### **Make significant progress in delivering the outcomes of the 2013 Publications Retreat**

- Progress has been made on several of the recommendations from the Retreat including: establishing the social media presence for the *British Journal of Pharmacology (BJP)* and the *British Journal of Clinical Pharmacology (BJCP)*, the appointment of a Senior Editor for Education, provision of altmetrics in our journals, and continued engagement with open access policy. Work will continue in 2015 following a joint Senior Editors meeting in December 2014.
- The Society reviewed the current contract with its publishers, Wiley. The review took into account many of the outcomes of the 2013 Retreat, and made recommendations to Council in September 2014 concerning the possible renegotiation of the Society's publishing contract. The agreed outcomes from that review will be carried forward to 2015.

##### **Develop and deliver a strategy for better engagement of our journals in emerging science nations**

- Our journals continued to be available at free or reduced cost via philanthropic initiatives to researchers at thousands of institutions around the world: *BJP* is available via HINARI in over 2,500 institutions, and *BJCP* is available via HINARI and the International Network for the Availability of Scientific Publications in over 3,500 institutions.
- The Society's journals – and these initiatives – were promoted at numerous international meetings including the World Congress of Basic and Clinical Pharmacology which was held for the first time in Africa in July 2014.
- *BJP* Editor-in-Chief, Professor Ian McGrath led a webinar targeted at authors based in China to advise on writing a scientific paper.

##### **Raise the profile and visibility of BPS journals**

- Visits to the journal homepages ([brjpharmacol.com](http://brjpharmacol.com) and [bjcp-journal.com](http://bjcp-journal.com)) increased by 10% on average during 2014 compared with the same point in 2013.
- The journals were promoted at 77 international, national, and specialist library conferences globally, and seven scientific conferences worldwide in 2014.
- The first issue of every volume of *BJP* and *BJCP* was made available for free to encourage readership and maximise exposure during the citation window.
- Free online access is offered for a limited time to introduce the journals to new readers. This has been promoted at conferences throughout the year.

---

## BRITISH PHARMACOLOGICAL SOCIETY

---

### TRUSTEES' REPORT (continued) FOR THE YEAR ENDED 31 DECEMBER 2014

---

- The *BJCP*'s 40th anniversary was celebrated with a special editorial from Editor-in-Chief Professor James Ritter and a series of YouTube videos with authors, editors and members in January 2014 and with a special issue of the journal in December 2014.
- A special *BJP* virtual issue was created for the World Congress of Basic and Clinical Pharmacology, *IUPHAR Reviews*, which was promoted in Cape Town and subsequent conferences.

#### **5. STRATEGIC OBJECTIVE: Explain the importance of pharmacology in the modern world by extending BPS education and outreach activities**

##### **Create and implement a coherent, measurable vision statement for BPS Outreach activities**

- The Council decided to remodel the Society's strategic objectives to include a more coherent vision of our outreach activities, supported by new metrics for the evaluating the impact of BPS Outreach, which were agreed in June 2014.
- The Society attended or sponsored eight science festivals across the UK. Volunteers helped to run eight 'hands-on' stands, and member-delivered public engagement talks reached approximately 300 members of the public.

##### **Support the provision of benchmarking in pharmacology degrees, subject to acceptance by QAA**

- Initial feedback indicates that the Society's Education function will be successful in ensuring that pharmacology will be used as an exemplar of a specialist subject. The Society will also contribute a description of the subject-specific skills and knowledge that a pharmacology graduate would be expected to possess over and above the threshold skills and attributes expected of all biomedical graduates. We expect this work, and broader input into related accreditation projects, to continue into 2015.

#### **6. STRATEGIC OBJECTIVE: Reflect the increasingly multi disciplinary nature of modern biomedical science by further developing BPS's collaborative activities with other Societies**

##### **Contribute to openness and transparency issues around Animal Welfare (particularly with regard to journals)**

- In May 2014, the Concordat on Openness on Animal Research was launched and the Society was among the original 72 signatories. As part of its commitment to the Concordat, BPS will be working to enhance its communication around the use of animals and to support its members in doing the same.
- BPS has continued to work with the UK Bioscience Coalition and Animal Sciences Group on a range of policy matters including changes to Schedule 24 of the Animal (Scientific Procedures) Act 1986.
- *BJP* Senior Editors are refining the journal submission system to improve reporting of animal research. Professor Ian McGrath shared these changes at a recent meeting organized by Society of Biology to encourage dialogue between the scientific community and attendees from the Home Office
- The Society continued to encourage open and honest dialogue about the use of animals in pharmacological research, including an educational event for journalists co-organised with the Science Media Centre in October 2014 on 'What can animals tell us about psychiatry?'

---

## BRITISH PHARMACOLOGICAL SOCIETY

---

### TRUSTEES' REPORT (continued) FOR THE YEAR ENDED 31 DECEMBER 2014

---

#### **Increase high impact joint activities with professional bodies where pharmacology is an affiliated or integrated discipline**

- The Society maintained its partnerships with other pharmacological societies and related disciplines, engaging in scientific meetings, educational and publishing activities with International and European representative bodies, as well as societies from Austria, Australia, the USA, Hong Kong, South Africa, Japan and India.
- Details were finalised for a series of joint meetings in 2015 with the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (Hong Kong – May), Austrian Pharmacological Society (Graz – September) and British Toxicology Society (Edinburgh – October).
- Ongoing participation in the Drug Discovery Pathways Group with The Society of Biology, Royal Society of Chemistry and Biochemical Society has provided a single representative voice on key issues and ensures pharmacology's continued role in developing solutions to meet the needs of the wider medicines research community. This was encapsulated by the group's joint statement on Pfizer's declared interest in taking over AstraZeneca in April 2014 which was widely reported by key media.

#### **7. STRATEGIC OBJECTIVE: Maintain the Society's central position in the promotion of clinical pharmacology, the promotion of safe and effective prescribing, and in the discovery and development of medicines in the UK**

#### **Conduct a review into the value of CPT to the NHS, and extract maximum value for Clinical Pharmacology from its findings**

- The Society's Clinical Pharmacology Section published a new report, entitled *A Prescription for the NHS: Recognising the value of clinical pharmacology and therapeutics*, to articulate the value of the medical speciality Clinical Pharmacology and Therapeutics (CPT). The report was launched in November 2014 at a special event at the House of Lords hosted by Lord Winston. The launch generated recognition by partner organizations and in the NHS, social media interest, and media coverage.
- While the Society began follow up activity in late 2014 to ensure maximum impact, 2015 will be focused on disseminating the report's findings across the regions and with workforce decision-makers.

#### **Continue to support the Prescribing Safety Assessment and develop a coherent plan for the future direction and implementation of this test**

- The Prescribing Safety Assessment (PSA) continued its progression through piloting phases in medical schools across the UK, with a record number of UK medical students participating in 2014. More than 7,100 final year students from 31 UK medical schools sat the assessment, compared with just over 4,900 students from 29 UK schools in 2013.
- The Society commissioned a business plan for the PSA, which was reviewed by the PSA Executive Committee in November 2014. Key recommendations included increasing reliability and security through the continued development of the question bank, strengthening the support of stakeholders for the assessment, and the development of new opportunities for lower stakes (summative) assessments in new markets.

#### **Explore a long term role for the PSA, in tandem with key partners**

- The 2014 commercial review of the PSA supported the decision to move to a 3-year business and development cycle, to which BPS and its partner, the Medical Schools Council, are now committed.

#### **Disseminate and assess the impact of new Clinical Careers resources**

- The Society was represented at a number of clinical careers events including the RCP Medical Careers Day. A new careers resource is currently being tested with attendees at such events.

---

## BRITISH PHARMACOLOGICAL SOCIETY

---

### TRUSTEES' REPORT (continued) FOR THE YEAR ENDED 31 DECEMBER 2014

---

#### FINANCIAL REVIEW

For the year ended 31 December 2014 the total funds of the Society have decreased by £12,517 (2013 - increased by £379,564). The overall decrease is made up of a decrease in unrestricted funds of £51,304 (2013 - increase of £513,536) and an increase in restricted funds of £38,787 (2013 - decrease of £133,972).

Gains on investment totalling £71,498 (2013 - £346,425) have contributed towards the overall movement in funds and are entirely attributable to unrestricted funds.

The resulting balance of total funds at 31 December 2014 amounted to £6,360,793 (2013 - £6,373,310) of which £5,867,266 (2013 - £5,918,570) is the unrestricted funds of the Society.

The Statement of Financial Activities on page 19 and the Balance Sheet on page 20 provide further details of the Society's financial performance for the year and its financial position at the year end.

#### Incoming Resources

Incoming resources for the year totalled £3,478,009 (2013 - £3,352,484) which is an increase of 3.7%. Importantly, charitable activity income from Journal publishing, which is the Society's main income source, has increased by 4.0% to £2,795,227 (2013 - £2,688,431).

Member numbers increased by 5.6% to 3,653 (2013 - 3,460) and membership subscription income increased by 11.3% to £121,392 (2013 - £109,020). The growth is predominantly in Associate Undergraduate Student numbers, reflecting the Society's longer-term approach to strengthening and growing the discipline of pharmacology. Consistent with the approach, such members pay no subscription.

Scientific Meetings income increased by £6,964 to £137,697 (2013 - £130,733) reflecting the success of Pharmacology 2014 as well as income from two other meetings.

Voluntary income is mostly for educational activities and is entirely restricted funding; it reduced by £19,960 to £261,255 (2013 - 281,215).

Investment income was £4,516 higher at £124,054 (2013 - £119,538) reflecting the higher amount invested throughout the year.

#### Expenditure on Charitable Activities

Expenditure on charitable activities totalled £3,481,912 (2013 - £3,251,172) which is a 7.1% increase of £230,740.

Journal publishing costs increased by £77,728 to £1,146,351 (2013 - £1,068,623); the direct costs have been carefully controlled and the increase in total costs is mainly a result of the net income from the journals which increased the amount payable to the publisher.

Expenditure on educational activities reduced by £101,441 to £752,456 (2013 - £853,897) predominantly due to lower levels of restricted fund activity for both the Integrative Pharmacology Fund and the Short Courses Fund.

#### Capital Expenditure

Capital expenditure totalled £165,176 (2013 - £67,920) of which £138,756 (2013 - £53,458) is the cost of the new database and associated website functionality that is being developed to support the Society's services, effectiveness and efficiency. The new database went live "behind" the existing website in June 2014 and deployment of the new website is planned for mid-2015.

---

## BRITISH PHARMACOLOGICAL SOCIETY

---

### TRUSTEES' REPORT (continued) FOR THE YEAR ENDED 31 DECEMBER 2014

---

#### Reserves Policy

The Trustees have reviewed the Society's financial strategy and decided to designate funds accordingly, as shown in note 23. The resulting balance on General Funds of £2,563,464 represents the reserves of the Society.

The Trustees have also examined the Society's method for calculating a reserve level that represents a figure that would allow it to fulfil its commitments to its members both in terms of operations and activities over a period of one to two years if its major source of revenue failed. The reserves reported at 31 December 2014 are in excess of that level and this allows the Society to consider additional activities to further its objectives.

#### Investment Policy and Performance

The Society holds investments with a value totalling £4,684,747 at 31 December 2014 (2013 - £3,860,264). The increase is a result of a review of cash deposits at the end of 2013 which concluded that additional funds were available to invest.

The investments are split between two portfolios; the liquidity reserve and the growth fund and both portfolios had a positive 12 months. The liquidity reserve increased by 3.48% (2013 - £4.08%) compared to the FTSE Gilt Index benchmark which increased by 13.86%. Over the same period, the growth fund portfolio increased by 3.70% (2013 - 16.54%) and this compares to a gain of 7.23% for the APCIMS Balanced benchmark. The total cash appreciation for the combined portfolio over the period was £206,811 after costs.

The investments are managed on behalf of the Society by an investment management company, Brewin Dolphin (BD) and BD act for the Society on a fully discretionary basis. They are required nevertheless to have regard for the Society's status as an educational and health charity and the Society specifically prohibits investments in tobacco companies. In addition, to maintain an impartial position, BD is also prohibited from investing directly in pharmaceutical companies.

The Society's investment strategy works together with its reserves policy and seeks to provide against sudden loss of income from its traditional activities and in particular loss of income from its publishing activities. The liquidity reserve proportion of funds is invested in fixed income investments in order to provide liquidity a short notice. The growth fund has a longer term time horizon and is therefore invested for capital growth, with a greater level of investment risk.

The range of assets selected provides diversification and the opportunity to add value at the appropriate stage of the economic cycle. The balance between the different kinds of investments in both portfolios are determined by the investment manager's judgement of future returns likely to be obtained on each class of investments, and a mandate to target a certain level of liquidity coincidental with the Trustees' perception of future financial risk to which the Society might become exposed.

Strategic benchmarks and structured reporting enables the Society to regularly review both the performance of BD and its portfolios. Finance and Risk Committee (FRC) met regularly throughout the year with the investment manager to review the entire portfolio and agree the relative strategic benchmarks from time to time. FRC reviewed the performance of the investments each time it met and worked with the investment manager to ensure the investments provided long-term growth ahead of inflation, income and liquidity.

#### Creditors Payment Policy

The Society's policy is to pay its suppliers within the terms of their contracts.

#### GOING CONCERN

After making appropriate enquiries, the Trustees have a reasonable expectation that the Society has adequate resources to continue in operational existence for the foreseeable future. For this reason they continue to adopt the going concern basis in preparing the financial statements.

TRUSTEES' REPORT (continued)  
FOR THE YEAR ENDED 31 DECEMBER 2014

---

**PLANS FOR FUTURE PERIODS**

Council has set the following objectives for the year to 31 December 2015:

**1. STRATEGIC PRINCIPLE: Achieving financial resilience**

- Implement a new Financial Strategy to reflect the long term objectives of the Society.
- Deliver new business development opportunities in support of the goal to diversify the Society's sources of revenue.

**2. STRATEGIC PRINCIPLE: Modernizing equality and diversity policy**

- Continue to demonstrate significant progress towards the agreed goal of 25% representation of women at BPS committees and activities.

**3. STRATEGIC OBJECTIVE: Greater matching of the Society's activities to the needs of the Membership**

- Define a grants and awards strategy that matches the needs of BPS's membership and supports pharmacology in the modern world, including through the provision of new or updated grant programmes
- Develop and agree a strategy to recruit more new members to the Society, for implementation from 2016.
- Make recommendations to foster productive relations with the Society's international members, and attract more international members to the Society.

**4. STRATEGIC OBJECTIVE: Developing an integrated publications strategy**

- Build links and share activities between the Society's journals and its Education function.
- Take steps to ensure business continuity and development across a range of areas, including through appointments to key positions, and negotiation of a new publishing contract.
- Foster links and joint approaches across all of the Society's publishing output

**5. STRATEGIC OBJECTIVE: Explain the importance of pharmacology in the modern world by extending BPS education and outreach activities**

- Update the Society's core pharmacology curriculum with reference to broader bioscience teaching practices, including through QAA benchmarking.
- Evaluate and implement options to produce a range of new learning opportunities for members and non-members, including through subject-specific e-learning.

**6. STRATEGIC OBJECTIVE: Reflect the increasingly multi-disciplinary nature of modern biomedical science by further developing BPS's collaborative activities with other Societies**

- Oversee the successful establishment of BPS Affinity Groups and their input into BPS's Scientific Programme, as part of the Society's attempt to match its activities to the needs of its members.
- Continue to demonstrate the role of clinical pharmacology in patient safety through the Prescribing Safety Assessment in collaboration with MSC Assessment.

**7. STRATEGIC OBJECTIVE: Maintain the Society's central position in the promotion of clinical pharmacology, the promotion of safe and effective prescribing, and in the discovery and development of medicines in the UK**

- Increase BPS's visibility and impact, including through enhanced Outreach, Media and Public Engagement activities.
- Deliver a review of BPS's policy activities, and a plan to enhance them, for example through the development of new and updated position statements.
- Receive the recommendations of the branding review, and implement across the Society.
- Redevelop and launch a new BPS website in line with the outcomes of the Society's Digital Strategy and Branding Review.
- Support the 2014 CPT in the NHS report, by ensuring its recommendations are taken forward appropriately.

---

## BRITISH PHARMACOLOGICAL SOCIETY

---

### TRUSTEES' REPORT (continued) FOR THE YEAR ENDED 31 DECEMBER 2014

---

#### STRUCTURE, GOVERNANCE AND MANAGEMENT

Reference and administrative details are shown in the schedule of members of the board and professional advisers on page 1 to 2 of the financial statements.

#### THE TRUSTEES

The Trustees of the charity are shown below with details of their attendance at the four Council meetings held in the year under review.

##### Officer Trustees

President	H P Rang (1)	4/4
President-Elect	D J Webb (1)	4/4
Honorary Treasurer	C R Hiley (1)	4/4

##### Elected Trustees

Joint Chair CHOPT(a)	A Galione	4/4
Joint Chair CHOPT (a)	A H Morice	4/4
	S Price	3/4
	D M Wood	2/4
	M P Seed	4/4
	A R Green	4/4

##### Co-opted Trustees

C Williams	4/4	(Until 31 December 2014)
A K Daly	4/4	(Until 31 December 2014)
D O Douglas	4/4	(Until 31 December 2014)

##### Appointed Trustee

E Mason	N/A	(From 1 January 2015)
---------	-----	-----------------------

**(1) Denotes Executive Committee Member at 31 December 2013**

**(a) CHOPT - Committee of Heads and Professors of Pharmacology and Therapeutics**

The Society's governing document is its Articles of Association and Rules. In 1994, the Society became a Company Limited by Guarantee and therefore has no share capital. In the event of its winding up, the members' liability is limited to £1 each.

At the Society's Annual General Meeting in December 2014, the overwhelming majority of members who voted, voted in favour of new Articles of Association and Rules which took effect from 1 January 2015. The intention of this change is to simplify decision-making, devolving all but key strategic and financial decisions to the core committees. The more significant changes have been:

- The abolition of the Executive Committee. Overall control and strategic direction of the Society remains with Council on behalf of members.
- A reduction in the number of operational committees and groups (from 27, many of which were dormant) to 14.
- The seven core committees, each chaired by a Vice-President or officer, will benefit from greater autonomy and control over their budgets.
- Some of the pre-existing committees (e.g. Women in Pharmacology, Young Pharmacologists, CHOPT) have been retained as Advisory Groups, in order to give advice to the Society's wider core committees, in addition to their function as much-valued discussion forums and sources of ideas.

---

## BRITISH PHARMACOLOGICAL SOCIETY

---

### TRUSTEES' REPORT (continued) FOR THE YEAR ENDED 31 DECEMBER 2014

---

The Trustees are legally responsible for the overall governance, strategy and direction of the Society. In terms of the Charities Act 2006, Trustees are accountable to the Charity Commission for ensuring that the Society's objectives as a registered charity are being met. The Trustees are also the Directors of the British Pharmacological Society. The Council of Trustees, which met four times (2013 three times), comprises the President (Chair), President Elect, Honorary Treasurer, Chairs of the Committee of Heads and Professors of Pharmacology and Therapeutics and four elected members (of whom at least one is from industry and one from the Clinical Pharmacology Section at the time of election).

The Trustees are empowered to appoint additional Trustees with specialist skills to assist in the governance of the Society. Appointed Trustees have the same responsibilities and powers as appointed Trustees and any such appointment shall be for such period as Council determines, subject to a maximum of three years, after which any person so appointed shall be eligible for election as a Trustee (including as an Officer) by the Voting Members, but shall not be re-appointed by the Council until a period of at least one year has elapsed after expiry of their term of office.

When considering elections for and appointment of Trustees, Council follows the requirements of the Society's constitution and Guidance Notes CC10 and CC30 of the Charity Commission:

- CC10 sets out the hallmarks of an effective charity, which includes a trustee board that *"has the right balance of skills and experience;"* and
- CC30 provides guidance on the processes involved noting that *"the existing trustees are legally responsible for the recruitment of new trustees" and in addition to taking account of diversity issues, trustees must "look at what skills, knowledge and experience are needed to make sure that the charity is well governed and is run effectively, efficiently and appropriately to its size and complexity"*.

Elections to the Council take place each year at the AGM and only members in good standing may be nominated as elected Trustees. With the exception of the Young Pharmacologist Trustee, all elected Trustees must be Voting Members. Trustees are elected to serve for periods of between three and four years, depending on office. In 2014 none of the elected Trustees' terms of office came to an end and so there were no elections. Despite the absence of elections, good member engagement as part of the consultation on changing the governance of the Society, ensured the number of votes cast was nonetheless maintained close to the higher numbers achieved in 2013 289 members voted in 2014 compared with 310 in 2013.

Job descriptions have been produced for Council members and are regularly reviewed to ensure they reflect reality. The job descriptions specify the knowledge, skills and attributes that are needed by the members. Trustee training is undertaken annually.

Council has delegated responsibility to a small Management Group, chaired by the President, to oversee the day to day operations of the Society; the Group also comprises the President-Elect, Honorary Treasurer and Chief Executive. Financial management is delegated to the Finance Committee chaired by the Honorary Treasurer. Each of the seven core committees are responsible for considering risk and reporting changes in the risk profile and actions required to Council.

The seven core committees to whom powers are delegated report back to Council. Members of these Committees and Groups comprise both Trustees and/or elected Vice-Presidents, together with other members. The Journals are managed by the Society's Publications Committee, which in turn delegates responsibility to the journals' Management and Editorial Boards.

---

## BRITISH PHARMACOLOGICAL SOCIETY

---

### TRUSTEES' REPORT (continued) FOR THE YEAR ENDED 31 DECEMBER 2014

---

The Council has ultimate responsibility for all aspects of the Society's activities, including management, with the exception of those matters which must be decided by a general meeting of the members. The Council focuses on strategy and the Management Group is delegated the responsibility for the general management of the Society's activities. The Trustees employ a Chief Executive who is responsible for executing the decisions of committees and sub committees and for the day to day management of the Society's resources, including the other employees, and the Angel Gate building. At 31 December 2014 we had 13 full time staff and utilised the services of specialist consultants as required. The Chief Executive reports back to Council and Management Group on performance against the objectives of BPS.

The Society benefits from a great deal of voluntary work by its members in the organisation of meetings, editing and refereeing of manuscripts, service on committees and panels, and many other activities. The Trustees thank these members for all of the activities they have undertaken on behalf of the Society.

The Society participates actively in the wider Bioscience community both in the UK and internationally, including but not limited to, collaborative funding of research and education initiatives and the hosting of scientific meetings. Details of these activities are included in the section on Achievements and Performance on pages 5 to 9.

#### **RISK ASSESSMENT**

The Council has a Risk Policy and a Risk Register which provide the framework for the management of risks and demonstrate the controls in place to mitigate them. The Risk Register is reviewed on a continuing basis by the Finance Committee and a report is made to the Executive Committee and Trustees. Risk mitigation includes the review and management of risk as an integral part of the business process.

The prime risk to which the Society is exposed continues to be financial, particularly in respect of the income from our journals. This risk is the predominant determinate of the level of free reserves held by the Society according to its Reserves Policy.

---

## BRITISH PHARMACOLOGICAL SOCIETY

---

### TRUSTEES' REPORT (continued) FOR THE YEAR ENDED 31 DECEMBER 2014

---

#### TRUSTEES' RESPONSIBILITIES STATEMENT

The Trustees (who are also directors of British Pharmacological Society for the purposes of company law) are responsible for preparing the Trustees' report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the Trustees to prepare financial statements for each financial year. Under company law the Trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that period. In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgments and accounting estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in operation.

The Trustees are responsible for keeping adequate accounting records that are sufficient to show and explain the charitable company's transactions and disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

#### DISCLOSURE OF INFORMATION TO AUDITOR

Each of the persons who are Trustees at the time when this Trustees' report is approved has confirmed that:

- so far as that Trustee is aware, there is no relevant audit information of which the charitable company's auditors are unaware, and
- that Trustee has taken all the steps that ought to have been taken as a Trustee in order to be aware of any information needed by the charitable company's auditors in connection with preparing their report and to establish that the charitable company's auditors are aware of that information.

This report was approved by the Trustees on

and signed on their behalf by:

**H P Rang**  
President

---

## BRITISH PHARMACOLOGICAL SOCIETY

---

### INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF BRITISH PHARMACOLOGICAL SOCIETY

---

We have audited the financial statements of the BRITISH PHARMACOLOGICAL SOCIETY for the year ended 31 December 2014 set out on pages 19 to 39. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

This report is made solely to the charity's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the charity's members those matters we are required to state to them in an Auditors' Report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charity and its members, as a body, for our audit work, for this report, or for the opinion we have formed.

#### RESPECTIVE RESPONSIBILITIES OF TRUSTEES AND AUDITORS

As explained more fully in the Trustees' responsibilities statement, the Trustees (who are also the directors of the charity for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view.

#### SCOPE OF THE AUDIT OF THE FINANCIAL STATEMENTS

An audit involves obtaining evidence about the amounts and disclosures in the financial statements sufficient to give reasonable assurance that the financial statements are free from material misstatement, whether caused by fraud or error. This includes an assessment of: whether the accounting policies are appropriate to the charity's circumstances and have been consistently applied and adequately disclosed; the reasonableness of significant accounting estimates made by the Trustees; and the overall presentation of the financial statements. In addition, we read all the financial and non-financial information in the Trustees' report to identify material inconsistencies with the audited financial statements and to identify any information that is apparently materially incorrect based on, or materially inconsistent with, the knowledge acquired by us in the course of performing the audit. If we become aware of any apparent material misstatements or inconsistencies we consider the implications for our report.

#### OPINION ON FINANCIAL STATEMENTS

In our opinion the financial statements:

- give a true and fair view of the state of the charity's affairs as at 31 December 2014 and of its incoming resources and application of resources, including its income and expenditure, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006.

#### OPINION ON OTHER MATTER PRESCRIBED BY THE COMPANIES ACT 2006

In our opinion the information given in the Trustees' report for the financial year for which the financial statements are prepared is consistent with the financial statements.

---

**BRITISH PHARMACOLOGICAL SOCIETY**

---

**INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF BRITISH PHARMACOLOGICAL SOCIETY**

---

**MATTERS ON WHICH WE ARE REQUIRED TO REPORT BY EXCEPTION**

We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion:

- adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
- the financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of trustees' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit; or

Jeffrey Meek CA (Senior statutory auditor)

for and on behalf of

**French Duncan LLP**

Chartered Accountants & Statutory Auditor

56 Palmerston Place

Edinburgh

EH12 5AY

Date:

**BRITISH PHARMACOLOGICAL SOCIETY**

**STATEMENT OF FINANCIAL ACTIVITIES  
FOR THE YEAR ENDED 31 DECEMBER 2014**

	Note	Restricted funds 2014 £	Unrestricted funds 2014 £	Total funds 2014 £	Total funds 2013 £
<b>INCOMING RESOURCES</b>					
Incoming resources from generated funds:					
Voluntary income	2	261,255	-	261,255	281,215
Investment income	3	-	124,054	124,054	119,538
Incoming resources from charitable activities	4	7,000	3,080,891	3,087,891	2,939,807
Other incoming resources	5	-	4,809	4,809	11,924
<b>TOTAL INCOMING RESOURCES</b>		<b>268,255</b>	<b>3,209,754</b>	<b>3,478,009</b>	<b>3,352,484</b>
<b>RESOURCES EXPENDED</b>					
Costs of generating funds:					
Investment management expenses	6	-	26,599	26,599	20,274
Charitable activities	8	257,468	3,224,444	3,481,912	3,251,172
Governance costs	11	-	53,513	53,513	34,090
Other resources expended	12	-	-	-	13,719
<b>TOTAL RESOURCES EXPENDED</b>		<b>257,468</b>	<b>3,304,556</b>	<b>3,562,024</b>	<b>3,319,255</b>
<b>NET INCOMING RESOURCES / (RESOURCES EXPENDED) BEFORE TRANSFERS</b>					
		10,787	(94,802)	(84,015)	33,229
Transfers between Funds	23	28,000	(28,000)	-	-
<b>NET INCOMING RESOURCES / (RESOURCES EXPENDED) BEFORE INVESTMENT ASSET DISPOSALS</b>					
		38,787	(122,802)	(84,015)	33,229
Gains and losses on disposals of investment assets	17	-	-	-	24,867
<b>NET INCOMING RESOURCES / (RESOURCES EXPENDED) BEFORE REVALUATIONS</b>					
		38,787	(122,802)	(84,015)	58,096
Unrealised gains and losses on revaluations of investment assets	17	-	71,498	71,498	321,558
<b>NET MOVEMENT IN FUNDS FOR THE YEAR</b>		<b>38,787</b>	<b>(51,304)</b>	<b>(12,517)</b>	<b>379,654</b>
<i>Total funds at 1 January 2014</i>		454,740	5,918,570	6,373,310	5,993,656
<b>TOTAL FUNDS AT 31 DECEMBER 2014</b>		<b>493,527</b>	<b>5,867,266</b>	<b>6,360,793</b>	<b>6,373,310</b>

All activities relate to continuing operations.  
The notes on pages 21 to 39 form part of these financial statements.

**BRITISH PHARMACOLOGICAL SOCIETY**  
**REGISTERED NUMBER: 2877400**

**BALANCE SHEET**  
**AS AT 31 DECEMBER 2014**

	Note	£	2014 £	£	2013 £
<b>FIXED ASSETS</b>					
Tangible assets	16		760,649		669,745
Investments	17		4,684,747		3,860,264
			5,445,396		4,530,009
<b>CURRENT ASSETS</b>					
Debtors	18	864,980		715,299	
Cash at bank and in hand		686,082		2,161,738	
		1,551,062		2,877,037	
<b>CREDITORS:</b> amounts falling due within one year	19	(554,790)		(930,795)	
<b>NET CURRENT ASSETS</b>			996,272		1,946,242
<b>TOTAL ASSETS LESS CURRENT LIABILITIES</b>			6,441,668		6,476,251
<b>CREDITORS:</b> amounts falling due after more than one year	20		(80,875)		(102,941)
<b>NET ASSETS</b>			6,360,793		6,373,310
<b>CHARITY FUNDS</b>					
Restricted funds	23		493,527		454,740
Unrestricted funds	23		5,867,266		5,918,570
<b>TOTAL FUNDS</b>			6,360,793		6,373,310

The financial statements were approved by the Trustees on behalf, by:

and signed on their

**C R Hiley**

**Honorary Treasurer**

The notes on pages 21 to 39 form part of these financial statements.

---

## BRITISH PHARMACOLOGICAL SOCIETY

---

### NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2014

---

#### 1. ACCOUNTING POLICIES

##### 1.1 Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention, with the exception of investments which are included at market value. The financial statements have been prepared in accordance with the Statement of Recommended Practice (SORP), 'Accounting and Reporting by Charities' published in March 2005, applicable accounting standards and the Companies Act 2006.

##### 1.2 Cash flow

The charity has taken advantage of the exemption in Financial Reporting Standard No.1 from the requirement to produce a cash flow statement on the grounds that it is a small charitable company.

##### 1.3 Fund accounting

Unrestricted funds are expendable at the discretion of the trustees in furtherance of the objects of the Charity. The Trustees may, from time to time, set aside certain funds for specific purposes into separate designated funds. Such designations carry no legal restrictions and may be changed at the discretion of the Trustees.

Designated funds are unrestricted funds earmarked by the trustees for particular purposes.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the charity for particular purposes. The costs of raising and administering such funds are charged against the specific fund. The aim and use of each restricted fund is set out in the notes to the financial statements.

Investment income, gains and losses are allocated to the appropriate fund.

##### 1.4 Incoming resources

All incoming resources are included in the Statement of Financial Activities when the charity is legally entitled to the income and the amount can be quantified with reasonable accuracy.

##### **Voluntary income and legacies**

Voluntary income derived by way of donations and legacies to the Charity is included in full in the Statement of Financial Activities when the Society has the legal entitlement to receive the funds and the Trustees are accurately able to assess the amount of the donation or legacy.

##### **Membership subscriptions**

Some membership dues are paid annually by the members for the year to 31 December. An amount of deferred income is recorded for subscriptions received in advance.

---

## BRITISH PHARMACOLOGICAL SOCIETY

---

### NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2014

---

#### 1. ACCOUNTING POLICIES (continued)

##### 1.5 Resources expended

All expenditure is accounted for on an accruals basis and has been included under expense categories that aggregate all costs for allocation to activities. Where costs cannot be directly attributed to particular activities they have been allocated on a basis consistent with the use of the resources.

Support costs are those costs incurred directly in support of expenditure on the objects of the charity and are allocated to the activity they relate to. General support costs are allocated to charitable activities based on the proportions of direct and grant related activity costs. Governance costs are those incurred in connection with administration of the charity and compliance with constitutional and statutory requirements.

Grants payable are charged in the year when the offer is made except in those cases where the offer is conditional, such grants being recognised as expenditure when the conditions attaching are fulfilled. Grants offered subject to conditions which have not been met at the year end are noted as a commitment, but not accrued as expenditure.

##### Grants awarded

Full provision is made for educational awards and bursaries when approved by the Trustees.

##### 1.6 Costs of generating funds

These are costs associated with raising voluntary income and investment income for the Charity.

##### 1.7 Allocation of overheads

Central overhead costs are allocated to activities on the basis of departmental salaries:

Member services	48%
Journal publishing costs	0%
Educational activities	28%
Projects and awards	0%
Scientific meetings	24%

##### 1.8 Charitable activities

These are costs associated with the Charity's charitable activities.

##### Journal publishing income and costs

This represents the income and expenditure involved in publishing the British Journal of Pharmacology and the British Journal of Clinical Pharmacology.

---

## BRITISH PHARMACOLOGICAL SOCIETY

---

### NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2014

---

#### 1. ACCOUNTING POLICIES (continued)

##### 1.9 Tangible fixed assets and depreciation

All assets costing more than £2,000 are capitalised.

Tangible fixed assets are stated at cost less depreciation. Depreciation is not charged on freehold land. Depreciation on other tangible fixed assets is provided at rates calculated to write off the cost of those assets, less their estimated residual value, over their expected useful lives on the following bases:

Leasehold property	-	none
Fixtures & fittings	-	over 5 - 8 years straight line
Computer equipment	-	over 3 years straight line
Computer software & website	-	over 3 years straight line

##### 1.10 Revaluation of tangible fixed assets

Leasehold property is carried at current year value at the balance sheet date. A full valuation is obtained from qualified valuer for the property every five years, with an interim valuation three years after the previous full valuation, and in any year where it is likely that there has been a material change in value.

Revaluation gains and losses are recognised in the statement of total recognised gains and losses unless losses exceed the previously recognised gains or reflect a clear consumption of economic benefits, in which case the losses are recognised in the Statement of Financial Activities.

##### 1.11 Investments

Investments are stated at the mid-market value ruling at the balance sheet date. The Statement of Financial Activities includes the net gains and losses arising on revaluations and disposals throughout the year.

##### 1.12 Company status

The Charity is a company limited by guarantee. The directors of the company are the Trustees named on page 12. In the event of the Charity being wound up, the liability in respect of the guarantee is limited to £1 per member of the Charity.

##### 1.13 Pensions

BPS participates in the Superannuation Arrangements of the University of London ("SAUL") which is a centralised defined benefit scheme and is contracted out of the Second State Pension.

SAUL is a "last person standing" scheme so that in the event of insolvency of any of the participating employers in SAUL, the amount of any pension funding shortfall (which cannot otherwise be recovered) in respect of that employer will be spread across the remaining participant employers and reflected in the next actuarial valuation. A formal valuation of SAUL is carried out every three years by professionally qualified and independent actuaries using the Projected Unit method. Informal reviews of SAUL's position are carried out between formal valuations. See Note 21.

**BRITISH PHARMACOLOGICAL SOCIETY**

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 DECEMBER 2014**

**1. ACCOUNTING POLICIES (continued)**

**1.14 Recognition of liabilities**

The Society recognises liabilities when there is a legal obligation to incur the liability and the amount can be reliably calculated.

**2. VOLUNTARY INCOME**

	<b>Restricted funds 2014 £</b>	<b>Unrestricted funds 2014 £</b>	<b>Total funds 2014 £</b>	<i>Total funds 2013 £</i>
Donations and grants	<b>261,255</b>	-	<b>261,255</b>	<i>281,215</i>

**3. INVESTMENT INCOME**

	<b>Restricted funds 2014 £</b>	<b>Unrestricted funds 2014 £</b>	<b>Total funds 2014 £</b>	<i>Total funds 2013 £</i>
Income from UK listed investments	-	<b>105,455</b>	<b>105,455</b>	<i>95,678</i>
Income from non-UK listed investments	-	<b>16,320</b>	<b>16,320</b>	<i>10,470</i>
Bank interest receivable	-	<b>2,279</b>	<b>2,279</b>	<i>13,390</i>
	-	<b>124,054</b>	<b>124,054</b>	<i>119,538</i>

**4. INCOMING RESOURCES FROM CHARITABLE ACTIVITIES**

	<b>Restricted funds 2014 £</b>	<b>Unrestricted funds 2014 £</b>	<b>Total funds 2014 £</b>	<i>Total funds 2013 £</i>
Membership subscriptions	-	<b>121,392</b>	<b>121,392</b>	<i>109,020</i>
Journal publishing income	-	<b>2,795,227</b>	<b>2,795,227</b>	<i>2,688,431</i>
Educational activities	-	<b>33,575</b>	<b>33,575</b>	<i>11,623</i>
Scientific meetings	<b>7,000</b>	<b>130,697</b>	<b>137,697</b>	<i>130,733</i>
	<b>7,000</b>	<b>3,080,891</b>	<b>3,087,891</b>	<i>2,939,807</i>

**BRITISH PHARMACOLOGICAL SOCIETY**

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 DECEMBER 2014**

**5. OTHER INCOMING RESOURCES**

	<b>Restricted funds 2014 £</b>	<b>Unrestricted funds 2014 £</b>	<b>Total funds 2014 £</b>	<i>Total funds 2013 £</i>
Other income	-	4,809	4,809	11,924

**6. INVESTMENT MANAGEMENT COSTS**

	<b>Restricted funds 2014 £</b>	<b>Unrestricted funds 2014 £</b>	<b>Total funds 2014 £</b>	<i>Total funds 2013 £</i>
Investment management fees	-	26,599	26,599	20,274

**7. EXPENDITURE BY CHARITABLE ACTIVITY**

**SUMMARY BY FUND TYPE**

	<b>Restricted funds 2014 £</b>	<b>Unrestricted funds 2014 £</b>	<b>Total funds 2014 £</b>	<i>Total funds 2013 £</i>
Members services	-	713,684	713,684	557,558
Journal publishing costs	-	1,146,351	1,146,351	1,068,623
Educational activities	237,330	515,126	752,456	853,897
Projects and awards	3,019	103,973	106,992	85,570
Scientific meetings	17,119	745,310	762,429	685,524
	<b>257,468</b>	<b>3,224,444</b>	<b>3,481,912</b>	<i>3,251,172</i>

**SUMMARY BY EXPENDITURE TYPE**

	<b>Staff costs 2014 £</b>	<b>Other costs 2014 £</b>	<b>Total 2014 £</b>	<i>Total 2013 £</i>
Members services	333,044	380,640	713,684	557,558
Journal publishing costs	-	1,146,351	1,146,351	1,068,623
Educational activities	194,275	558,181	752,456	853,897
Projects and awards	-	106,992	106,992	85,570
Scientific meetings	166,521	595,908	762,429	685,524
	<b>693,840</b>	<b>2,788,072</b>	<b>3,481,912</b>	<i>3,251,172</i>

**BRITISH PHARMACOLOGICAL SOCIETY**

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 DECEMBER 2014**

**8. ANALYSIS OF RESOURCES EXPENDED BY ACTIVITIES**

	Activities undertaken directly 2014 £	Grant funding of activities (note 9/10) 2014 £	Support costs 2014 £	Total 2014 £	<i>Total</i> 2013 £
Members services	713,684	-	-	713,684	557,558
Journal publishing costs	1,146,351	-	-	1,146,351	1,068,623
Educational activities	655,355	97,101	-	752,456	853,897
Projects and awards	44,420	62,572	-	106,992	85,570
Scientific meetings	744,910	17,519	-	762,429	685,524
<b>Total</b>	<b>3,304,720</b>	<b>177,192</b>	<b>-</b>	<b>3,481,912</b>	<b>3,251,172</b>

**9. GRANTS TO INDIVIDUALS**

	Number 2014	Total 2014 £	<i>Number</i> 2013	<i>Total</i> 2013 £
A J Clark Studentships	1	24,739	2	99,428
Bain Awards	113	62,572	121	46,352
World Pharma 2014 (see note 23)	1	17,119		-
Teaching grant	1	400		-
	<b>116</b>	<b>104,830</b>	<b>123</b>	<b>145,780</b>

The Bain Awards represent 113 grants of between £13 and £1,300 (2013 - 121 grants of between £27 and £1,386) to assist individuals to attend conferences.

Included within the 2014 AJ Clark Studentships figure is the reversal of a prior year commitment of £63,808 due to the withdrawal of an awardee from their course.

**BRITISH PHARMACOLOGICAL SOCIETY**

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 DECEMBER 2014**

**10. GRANTS TO INSTITUTIONS**

	<b>Total funds 2014 £</b>	<i>Total funds 2013 £</i>
Educational activities	<b>72,362</b>	<i>416,763</i>
	<b>2014 £</b>	<i>2013 £</i>
In Vivo Short Courses	<b>51,835</b>	<i>89,290</i>
In Vivo Training	<b>36,397</b>	<i>33,857</i>
Medical Research Council Capacity Building Studentship Top Ups	<b>(23,018)</b>	<i>237,000</i>
Prescribing Safety Assessment	-	<i>56,137</i>
Support Costs	-	<i>479</i>
Outreach Funding	<b>5,092</b>	-
EPHAR	<b>2,056</b>	-
Total	<b>72,362</b>	<i>416,763</i>

*In Vivo* Short Courses and Training grants are given to universities for educational purposes. During the year 14 (2013 - 14) awards of between £2,344 and £35,000 (2013 - £500 and £25,000) were made.

Medical Research Council Capacity Building Studentship Top Ups are given to universities to defray the costs of consumables incurred by students as part of their *In Vivo* techniques training. During the year, 5 (2013 - 11) universities were given awards of between £15,000 and £35,000 (2013 - £500 and £40,000).

**11. GOVERNANCE COSTS**

	<b>Restricted funds 2014 £</b>	<b>Unrestricted funds 2014 £</b>	<b>Total funds 2014 £</b>	<i>Total funds 2013 £</i>
Governance Internal audit costs	-	<b>2,500</b>	<b>2,500</b>	<i>2,500</i>
Governance Auditors' remuneration	-	<b>10,039</b>	<b>10,039</b>	<i>9,028</i>
Council - travel and meetings	-	<b>14,296</b>	<b>14,296</b>	<i>12,169</i>
Legal and professional fees	-	<b>26,678</b>	<b>26,678</b>	<i>10,393</i>
	-	<b>53,513</b>	<b>53,513</b>	<i>34,090</i>

---

BRITISH PHARMACOLOGICAL SOCIETY

---

NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 DECEMBER 2014

---

12. OTHER RESOURCES EXPENDED

	Restricted funds 2014 £	Unrestricted funds 2014 £	Total funds 2014 £	Total funds 2013 £
Loss on disposal of tangible fixed assets for charity's own use	-	-	-	13,719

13. INCOMING RESOURCES

84% of the Charity's journal publishing income (2013 - 83%) is attributable to geographical markets outside the United Kingdom.

All other incoming resources are attributable to the United Kingdom.

14. NET INCOMING RESOURCES / (RESOURCES EXPENDED)

This is stated after charging:

	2014 £	2013 £
Depreciation of tangible fixed assets: - owned by the charity	74,272	13,150
Auditors' remuneration	10,039	9,028
Governance Internal audit costs	2,500	2,500

During the year, no Trustees received any remuneration (2013 - £NIL).

During the year, 8 (2013 - 8) Trustees were reimbursed for travel and subsistence and other general expenses totalling £10,984 (2013 - £17,079).

Included within Trustees' expenses is £2,500 (2013 - £2,500) in respect of fees paid to D O Douglas in respect of accountancy and internal audit services.

---

BRITISH PHARMACOLOGICAL SOCIETY

---

NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 DECEMBER 2014

---

15. STAFF COSTS

Staff costs were as follows:

	2014 £	2013 £
Wages and salaries	589,796	552,750
Social security costs	46,880	49,694
Pension costs	57,163	48,501
	<u>693,839</u>	<u>650,945</u>

The average monthly number of employees during the year was as follows:

	2014 No.	2013 No.
	<u>14</u>	<u>12</u>

The number of higher paid employees was:

	2014 No.	2013 No.
In the band £70,001 - £80,000	1	0
In the band £90,001 - £100,000	1	1
	<u>2</u>	<u>1</u>

Included within wages and salaries are honoraria payments to members of £4,668 (2013 - £6,000).

BRITISH PHARMACOLOGICAL SOCIETY

NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 DECEMBER 2014

16. TANGIBLE FIXED ASSETS

	Leasehold property £	Fixtures & fittings £	Computer equipment £	Computer Software & website £	Total £
<b>Cost or Valuation</b>					
At 1 January 2014	590,000	128,290	110,623	-	828,913
Additions	-	21,241	5,179	138,756	165,176
Disposals	-	(37,333)	(19,518)	-	(56,851)
Transfer between classes	-	-	(58,417)	58,417	-
At 31 December 2014	<u>590,000</u>	<u>112,198</u>	<u>37,867</u>	<u>197,173</u>	<u>937,238</u>
<b>Depreciation</b>					
At 1 January 2014	-	113,020	46,148	-	159,168
Charge for the year	-	8,296	5,206	60,770	74,272
On disposals	-	(37,333)	(19,518)	-	(56,851)
At 31 December 2014	<u>-</u>	<u>83,983</u>	<u>31,836</u>	<u>60,770</u>	<u>176,589</u>
<b>Net book value</b>					
At 31 December 2014	<u>590,000</u>	<u>28,215</u>	<u>6,031</u>	<u>136,403</u>	<u>760,649</u>
<i>At 31 December 2013</i>	<u>590,000</u>	<u>15,270</u>	<u>64,475</u>	<u>-</u>	<u>669,745</u>

Included in computer software & website (2013 - computer equipment) are assets in the course of construction with a carrying value of £11,445 (2013 - £58,417) which have not been depreciated as they were not in use as at the year end date.

**Revaluation of fixed assets**

The long leasehold property was revalued on 24 February 2010 at "Existing Use" value by Altus Edwin Hill, Chartered Surveyors at £590,000, a reduction of £30,000 since the last valuation on 20 May 2005. The historic cost of the property is £273,816.

The value of this property was reviewed on a market comparison basis in 2013 and there was no significant change from the 2010 valuation. A full professional valuation will be performed in 2015.

---

**BRITISH PHARMACOLOGICAL SOCIETY**

---

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 DECEMBER 2014**

---

**17. FIXED ASSET INVESTMENTS**

	<b>Listed securities £</b>
<b>Market value</b>	
At 1 January 2014	3,860,264
Additions	2,192,276
Disposals	(1,257,667)
Revaluations	(110,126)
	4,684,747
At 31 December 2014	4,684,747
<b>Historical cost</b>	4,003,932

**Investments at market value comprise:**

	UK £	Overseas £	2014 £	2013 £
Listed investments	3,658,409	1,026,338	4,684,747	3,860,264
	3,658,409	1,026,338	4,684,747	3,860,264

The above investments are all in relation to unrestricted funds.

**18. DEBTORS**

	2014 £	2013 £
Trade debtors	80,380	15,477
VAT	-	3,059
Other debtors	704,050	654,543
Prepayments and accrued income	80,550	42,220
	864,980	715,299

Other debtors mainly represents the final installment of the journal publishing income due but unpaid at the year end.

**BRITISH PHARMACOLOGICAL SOCIETY**

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 DECEMBER 2014**

**19. CREDITORS:  
Amounts falling due within one year**

	2014 £	2013 £
Trade creditors	204,263	225,040
Other taxation and social security	20,001	-
Other creditors	235,862	616,146
Accruals and deferred income	94,664	89,609
	554,790	930,795
	554,790	930,795

Included within other creditors is an amount of £52,500 (2013 - £350,000) in respect of Integrative Pharmacology Fund commitments, £57,179 (2013 - £67,882) in respect of A J Clark Fund commitments, £80,000 (2013 - £145,500) in respects of *In Vivo* Short Courses Fund commitments and £34,374 (2013 - £38,700) in respect of *In Vivo* Training Fund commitments in line with the Society's accounting policy.

**Deferred income**

The movement of deferred income, included within accruals and deferred income above, during the year was as follows:

	Membership income £	Other income including grants £	Total £
At 1 January 2014	18,111	-	18,111
Movement during the year	1,681	-	1,681
	19,792	-	19,792
	19,792	-	19,792

Membership income related to subscriptions received in advance.

**20. CREDITORS:  
Amounts falling due after more than one year**

	2014 £	2013 £
Grant awards	80,875	102,941
	80,875	102,941
	80,875	102,941

---

## BRITISH PHARMACOLOGICAL SOCIETY

---

### NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2014

---

#### 21. PENSION COMMITMENTS

BPS participates in a centralised defined benefit scheme for all qualified employees with the assets held in separate Trustee-administered funds (SAUL). The BPS has now adopted FRS17 for accounting for pension costs. It is not possible to identify the BPS's share of the underlying assets and liabilities of SAUL. Therefore contributions are accounted for as if SAUL were a defined contribution scheme and pension costs are based on the amounts actually paid (i.e. cash amounts) in accordance with paragraphs 8 - 12 of FRS17.

SAUL is subject to triennial valuations by professionally qualified and independent actuaries. The last available valuation was carried out as at 31 March 2011 using the projected unit credit method in which the actuarial liability makes allowance for projected earnings. The main assumptions used to assess the technical provisions were:

	31 March 2011
Discount Rate	
- pre-retirement	6.80%
-post-retirement	4.70%
General Salary Increases	3.75% p.a until 31 March 2014, 4.50% p.a thereafter
Retail Prices Index Inflation (RPI)	3.50% p.a
Consumer Prices Index Inflation (CPI)	2.80% p.a
Pension Increases in payment (excess over GMP)	2.80% p.a
Mortality - base table	SAPS Nominal (year of both) tables with an age rating of +0.5 years for mates and -0.4 years for females.
Mortality - future improvements	Future improvements in line with CMI 2010 projections with a long term trend rate of 1.25% p.a.

\* an additional allowance is made for promotional Salary Increases

The actuarial valuation applies to SAUL as a whole and does not identify surpluses or deficits applicable to individual employers. As a whole, the market value of SAUL's assets was £1,506 million representing 95% of the liability for benefits after allowing for future increases in salaries.

Based on the strength of the Employer covenant and the Trustee's long-term investment strategy, the Trustees and the Employer agreed to maintain Employer and Member contributions at 13% of salaries and 6% of salaries respectively following the valuation. The above rates will be reviewed when the results of the next formal valuation (as at 31 March 2014) are known.

A comparison of SAUL's assets and liabilities calculated using assumptions consistent with FRS17 revealed SAUL to be in deficit at the last formal valuation date (31 March 2011). As part of this valuation, the Trustees and Employer have agreed that no additional contributions will be required to eliminate the current shortfall.

The more material changes (the introduction of a Career Average Revalued Earnings, or "CARE" benefit structure) to SAUL's benefit structure apply from 1 July 2012. As a consequence, the cost of benefit accrual is expected to fall as existing final salary members are replaced by new members joining the CARE structure. This will allow an increasing proportion of the expected asset return to be used to eliminate the funding shortfall. Based on conditions as at 31 March 2011, the shortfall is expected to be eliminated by 31 March 2021, which is ten years from the valuation date.

---

**BRITISH PHARMACOLOGICAL SOCIETY**

---

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 DECEMBER 2014**

---

**22. CONTINGENT LIABILITIES**

During the year, contributions towards In Vivo Short Courses totalling £65,000 (2013 - £110,000) were received or invoiced in by the Society and have been recognised as income within the Statement of Financial Activities. These courses are not scheduled to be held until 2015. If these courses do not take place then there is a possibility that these funds will need to be refunded to the original contributors.

**23. STATEMENT OF FUNDS**

	Brought Forward £	Incoming resources £	Resources Expended £	Transfers in/out £	Gains/ (Losses) £	Carried Forward £
<b>Designated funds</b>						
World Pharma 2022	50,000	-	-	450,000	-	500,000
World Pharma 2018	-	-	-	3,155	-	3,155
Prizes and awards Guide to Pharmacology Business Development Fixed Asset	-	-	-	1,000,000 600,000 500,000 760,649	-	1,000,000 600,000 500,000 760,649
	<u>50,000</u>	<u>-</u>	<u>-</u>	<u>3,313,804</u>	<u>-</u>	<u>3,363,804</u>
<b>General funds</b>						
General Funds	<u>5,868,570</u>	<u>3,209,754</u>	<u>(3,304,556)</u>	<u>(3,341,804)</u>	<u>71,498</u>	<u>2,503,462</u>
Total Unrestricted funds	<u>5,918,570</u>	<u>3,209,754</u>	<u>(3,304,556)</u>	<u>(28,000)</u>	<u>71,498</u>	<u>5,867,266</u>

**BRITISH PHARMACOLOGICAL SOCIETY**

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 DECEMBER 2014**

**Restricted funds**

	Brought Forward £	Incoming resources £	Resources Expended £	Transfers in/out £	Gains/ (Losses) £	Carried Forward £
In Vivo Training Fund	21,352	2,500	(36,397)	20,000	-	7,455
In Vivo Short Courses Fund	12,988	65,000	(67,465)	25,000	-	35,523
Wellcome Gold Medal Fund	2,000	-	(400)	-	-	1,600
Paton Fund	6,016	-	(726)	-	-	5,290
GRAC Fund	793	-	(793)	-	-	-
Gary Price Fund	8,582	-	-	-	-	8,582
Schachter Fund	7,516	-	(500)	-	-	7,016
Integrative Pharmacology Fund	137,029	-	23,018	(55,000)	-	105,047
E-Learning for Healthcare "Prescribe" Initiative Fund	141,769	60,000	(41,700)	-	-	160,069
AstraZeneca Women in Pharmacology Prize Fund	5,000	-	(1,000)	-	-	4,000
MRC Short Course in Translational Pharmacology Fund	40,562	-	-	(17,118)	-	23,444
Prescribing Safety Assessment Business Development Fund	68,833	130,000	(104,132)	38,000	-	132,701
Other prizes and awards	-	10,005	(10,005)	-	-	-
World Pharma 2014 Bursaries Fund	2,300	750	(250)	-	-	2,800
	-	-	(17,118)	17,118	-	-
	<u>454,740</u>	<u>268,255</u>	<u>(257,468)</u>	<u>28,000</u>	<u>-</u>	<u>493,527</u>
Total of funds	<u><u>6,373,310</u></u>	<u><u>3,478,009</u></u>	<u><u>(3,562,024)</u></u>	<u><u>-</u></u>	<u><u>71,498</u></u>	<u><u>6,360,793</u></u>

---

## BRITISH PHARMACOLOGICAL SOCIETY

---

### NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2014

---

#### 23. STATEMENT OF FUNDS (continued)

##### Designated Funds:

##### World Pharma 2022

The Society will be hosting the 2022 IUPHAR World Congress of Pharmacology, its bid to do so having been successful in July 2014, and £500,000 has been designated to fully underwrite the potential net cost of the event.

##### World Pharma 2018

The Society has designated funds for bursaries for 2018 IUPHAR World Congress of Pharmacology in Japan.

##### Prizes and Awards

This fund aims to provide income and capital growth to finance a proportion of the Society's charitable grants to individuals.

##### Guide to Pharmacology

This fund will enable the Society's intended commitment to production of the *Guide to Pharmacology* to be funded until October 2020.

##### Business Development

This fund will enable the Society to invest in innovation and product development activities to achieve the aims of revenue diversification and growth.

##### Fixed Assets

The Society owns one long leasehold property in London and a variety of other fixed assets. This fund represents the net book value of such assets.

##### Restricted Funds:

##### *In Vivo* Training Fund

This fund consists of contributions from pharmaceutical companies and the Society to support *In Vivo* pharmacology training within certain bachelors and masters degree courses in universities in the UK.

##### *In Vivo* Short Courses Fund

This fund uses contributions by the Society, the Physiological Society, industry and research bodies to support short courses in *In Vivo* pharmacology and physiology. These courses are held at universities nationwide. The courses are fully funded from contributions from the Medical Research Council, Wellcome Trust, the Physiological Society and the BPS Integrative Pharmacology Fund.

##### Wellcome Gold Medal Fund

This fund provides a biennial prize and medal, funded by GlaxoSmithKline, for outstanding contributions to pharmacology including ideas, techniques equipment etc, used in the development of experimental pharmacology.

NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 DECEMBER 2014

---

23. STATEMENT OF FUNDS (continued)

**Paton Fund**

This fund was established jointly by Sir William Paton and the Society to support costs and expenses for those studying the history of pharmacology including ideas, techniques equipment etc. used in the development of experimental pharmacology.

**GRAC Fund**

This fund was donated by Pfizer to facilitate compilation, production and distribution of the Society's publication "Guide to Receptors and Channels".

**Gary Price Fund**

This fund, in memory of the late Dr Gary Price, is funded by a single donation from GlaxoSmithKline to support lectures at BPS meetings.

**Schachter Fund**

This is funded by donations from Mrs Ruth Schachter, provides grants to Student Members of the Society to visit other laboratories to learn techniques or to attend certain meetings.

**Integrative Pharmacology Fund**

This fund which was established by AstraZeneca, GlaxoSmithKline and Pfizer, supports research and training in integrative pharmacology and related disciplines with the objective of building capacity and ensuring the discipline's long-term viability in the UK. During the year, donations were approved from this fund of £25,000 (2013 - £25,000) to the *In Vivo* Short Courses Fund, £20,000 (2013 - £20,000) to the *In Vivo* Training Fund and £10,000 (2013 - £10,000) was charged as an administrative fee to BPS in respect of administration of the fund. All of the above amounts have been shown as transfers in the year.

**E-Learning for Healthcare "Prescribe Initiative Fund"**

This fund was provided by the Department of Health to facilitate payments to BPS members contributing to the authoring and review of e-learning modules being developed between the Society and Department of Health, for the 38,000 medical students who train each year in the UK.

**AstraZeneca Women in Pharmacology Prize Fund**

This fund was created by a donation from AstraZeneca to provide the Society with a prize fund to recognise women whose career achievements have contributed significantly to our understanding of a particular field through excellence in research.

**MRC Short Course in Translational Pharmacology Fund**

This fund was established by a capacity building grant from the Medical Research Council to enable the Society to develop and run a programme in 2010 in translational pharmacology that is suitable for eligible researchers from all biomedical disciplines involved in drug discovery and translational process.

---

BRITISH PHARMACOLOGICAL SOCIETY

---

NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 DECEMBER 2014

---

23. STATEMENT OF FUNDS (continued)

**World Pharma 2014 Bursaries Fund**

This fund was established with money received in the year ended 31 December 2013 to fund bursaries for Young Pharmacologists to attend the World Congress of Pharmacology held in Cape Town, South Africa in July 2014.

**Prescribing Safety Assessment Fund**

This fund arose through the transfer of the balance of funds of a project initiated by the Dept. of Health. The project will now be continued by the BPS in conjunction with the Medical Schools Council to develop an assessment for final year medical students in prescribing.

**Business Development Fund**

This fund was established following the receipt of funding from a government-backed service offering support to businesses with the potential to improve and grow.

**Other prizes and awards**

From time to time the Society receives donations to enable it to provide grants or prizes related to ad hoc projects or initiatives.

Subject to the above, the Society has sufficient resources to enable these funds to be applied in accordance with their respective restrictions.

**SUMMARY OF FUNDS**

	<b>Brought Forward</b>	<b>Incoming resources</b>	<b>Resources Expended</b>	<b>Transfers in/out</b>	<b>Gains/ (Losses)</b>	<b>Carried Forward</b>
	<b>£</b>	<b>£</b>	<b>£</b>	<b>£</b>	<b>£</b>	<b>£</b>
Designated funds	50,000	-	-	3,313,804	-	3,363,804
General funds	5,868,570	3,209,754	(3,304,556)	(3,341,804)	71,498	2,503,462
	<u>5,918,570</u>	<u>3,209,754</u>	<u>(3,304,556)</u>	<u>(28,000)</u>	<u>71,498</u>	<u>5,867,266</u>
Restricted funds	454,740	268,255	(257,468)	28,000	-	493,527
	<u>6,373,310</u>	<u>3,478,009</u>	<u>(3,562,024)</u>	<u>-</u>	<u>71,498</u>	<u>6,360,793</u>

---

BRITISH PHARMACOLOGICAL SOCIETY

---

NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 DECEMBER 2014

---

24. ANALYSIS OF NET ASSETS BETWEEN FUNDS

	Restricted funds 2014 £	Unrestricted funds 2014 £	Total funds 2014 £	Total funds 2013 £
Tangible fixed assets	-	760,647	760,647	669,744
Fixed asset investments	-	4,684,747	4,684,747	3,860,264
Current assets	546,027	1,005,036	1,551,063	2,877,037
Creditors due within one year	(52,500)	(502,289)	(554,789)	(930,794)
Creditors due in more than one year	-	(80,875)	(80,875)	(102,941)
	<u>493,527</u>	<u>5,867,266</u>	<u>6,360,793</u>	<u>6,373,310</u>

25. CONTROLLING PARTY

In the opinion of the Trustees there is no ultimate controlling party.